The sea change in public opinion regarding marijuana use has led to significant shifts in the legal landscape across the United States. As of October 2022, the potential for a pivotal move in federal policy on marijuana classification has been set in motion. President Biden has issued an executive order directing both the Department of Health and Human Services and the Department of Justice to review its current categorization.
Presently, marijuana is listed as a “Schedule I” drug, implying high potential for abuse with no currently accepted medical use. Should the federal government decide to reclassify it as a “Schedule III” drug, this would indicate that marijuana, while still possessing potential for abuse, has established therapeutic applications and lower physical or psychological dependence compared to Schedule I and II substances.
The implications of this change, if it takes place, will run deep. This comparison of a Schedule I drug to a Schedule III drug survey reveals substantial differences in the legal rules and societal perceptions tied to each categorization. Yet, the consequences for corporations and legal professionals operating in this space are still undefined.
Many may be pondering on the question “What does this shift mean in terms of the law? Will this lead to a more open legal market for marijuana, currently restricted under federal law? Or may there still be a myriad of regulations, compliance matters, and enforcement actions even with a reclassified status?” So, with this potential change on the horizon, grasping the legal implications is essential for every actor in this space.
For a full examination and discussion of this potential change to marijuana classification, please refer to this informative article on the topic from JD Supra, written by experts from the law firm McAfee & Taft.